Evofem Biosciences Enters Material Definitive Agreement
Ticker: EVFM · Form: 8-K · Filed: Sep 6, 2024 · CIK: 1618835
Sentiment: neutral
Topics: material-definitive-agreement, corporate-update
Related Tickers: EVFM
TL;DR
EVFM signs a big deal, details TBD.
AI Summary
Evofem Biosciences, Inc. announced on September 6, 2024, that it has entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement, its terms, or any associated dollar amounts. The company's principal executive offices are located at 7770 Regents Road, Suite 113-618, San Diego, California 92122.
Why It Matters
This filing indicates a significant new development for Evofem Biosciences, potentially impacting its future operations and financial standing. Investors will be looking for further details on the nature of this agreement.
Risk Assessment
Risk Level: medium — The lack of specific details in the 8-K filing regarding the material definitive agreement introduces uncertainty and potential risk for investors.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- September 6, 2024 (date) — Date of earliest event reported
- 7770 Regents Road , Suite 113-618 San Diego , California 92122 (address) — Principal executive offices
- Neothetics, Inc. (company) — Former company name
FAQ
What is the nature of the Material Definitive Agreement entered into by Evofem Biosciences?
The filing does not specify the nature of the Material Definitive Agreement.
When did Evofem Biosciences enter into this Material Definitive Agreement?
The earliest event reported in the filing is September 6, 2024.
What are the principal executive offices of Evofem Biosciences?
The principal executive offices are located at 7770 Regents Road, Suite 113-618, San Diego, California 92122.
Has Evofem Biosciences undergone a name change previously?
Yes, the company was formerly known as Neothetics, Inc., with a name change date of September 5, 2014.
What is the SIC code for Evofem Biosciences?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,790 words · 7 min read · ~6 pages · Grade level 14.8 · Accepted 2024-09-06 16:00:17
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share EVFM OTCQB Indicate by
- $20,000,000 — net proceeds to Parent of no less than $20,000,000. On September 6, 2024, the Company, A
Filing Documents
- form8-k.htm (8-K) — 49KB
- ex2-1.htm (EX-2.1) — 22KB
- 0001493152-24-035285.txt ( ) — 246KB
- evfm-20240906.xsd (EX-101.SCH) — 3KB
- evfm-20240906_lab.xml (EX-101.LAB) — 33KB
- evfm-20240906_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: September 6, 2024 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer